DOKSORUBICIN-SIKLOFOSFAMID BILAN KIMYOTERAPIYADA TRIMETAZIDINNING MIOKARDNING KAPIYAROMETRIK PARAMETRLARIGA TA'SIRI
##article.subject##:
kimyoterapiya, kardiotoksiklik, miokard ishemiyasi, mikrosirkulyatsiya, kardionkologiya##article.abstract##
AC kimyoterapiya ko'krak saratoni uchun saratonga qarshi davolashning oltin standartidir. Yuqoridagi kimyoterapiya rejimining tarkibiy qismlari doksorubitsin va siklofosfamiddir. Ikkala dori ham aniq sitotoksik va sitostatik ta'sirga qo'shimcha ravishda, keng tarqalgan o'zgaruvchan yurak belgilari bilan namoyon bo'ladigan sezilarli kardiotoksik potentsialga ega. Ushbu tadqiqotda AC kimyoterapiya rejimining miokardning kapillyar o'zaniga ta'siri, trimetazidinning kapillyar-himoya ta'siri o'rganildi.
Библиографические ссылки
Avagimyan A., Kakturskiy L., Heshmat-Ghahdarijani K., Pogosova N., Sarrafzadegan N. Anthracycline Associated Disturbances of Cardiovascular Homeostasis. Curr Probl Cardiol. 2021. Article N: 100909. doi: 10.1016/j.cpcardiol.2021.100909.
Avagimyan A., Kakturskiy L. The impact of trimetazidine on the anthropometric parameters of doxorubicin-cyclophosphamide mode in chemotherapy-induced heart alteration. Georgian Med News. 2022;(322):158-161.
Avagimyan A.A., Mkrtchyan L.H., Gevorkyan A.A., Kononchuk N.B., Kakturskiy L.V., Djndoyan Z.T. Relationship between chemotherapy and atrial fibrillation: clinical case. Rational Pharmacotherapy in Cardiology. 2021;17(5):785-791.https://doi.org/10.20996/1819-6446-2021-10-17
López-Sendón J, Álvarez-Ortega C, Zamora Auñon P, Buño Soto A, Lyon AR, et al. Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. Eur Heart J. 2020;41(18):1720-1729. doi: 10.1093/eurheartj/ehaa006.
Kimberly-Louise R. In Vitro Evaluation of Anthracycline-induced Cardiotoxicity and Mitigation by Perturbation of Angiotensin Signalling, Durham theses, Durham University. 2018. Available at Durham E-Theses Online: http://etheses.dur.ac.uk/12609/.
Bhagat A, Kleinerman ES. Anthracycline-Induced Cardiotoxicity: Causes, Mechanisms, and Prevention. Adv Exp Med Biol. 2020;1257:181-192. doi: 10.1007/978-3-030-43032-0_15.
Avagimyan A.A., Mkrtchyan L.G., Kononchuk N.B., Kaktursky L.V., Agati L. Chemotherapy as a possible trigger for the myocardial lipomatosis development. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2021;27(6):706-712.
Kochetkova I.V., Chernykh T.M., Panyushkina G.M. An experience of trimetazidine usage in comorbidity. Russian Journal of Cardiology. 2018;(3):37-42.
Boldueva S.A., Leonova I.A., Zakharova O.V. Efficacy of Trimetazidine and Sulodexide in Patients with Microvascular Angina. Rational Pharmacotherapy in Cardiology. 2020;16(3):363-369. (In Russ.)https://doi.org/10.20996/1819-6446-2020-06-12
Sheibani M, Nezamoleslami S, Faghir-Ghanesefat H, Emami AH, Dehpour AR. Cardioprotective effects of dapsone against doxorubicin-induced cardiotoxicity in rats. Cancer Chemother Pharmacol. 2020;85(3):563-571. doi: 10.1007/s00280-019-04019-6.
Omole JG, Ayoka OA, Alabi QK, Adefisayo MA, Asafa MA, Olubunmi BO, Fadeyi BA. Protective Effect of Kolaviron on Cyclophosphamide-Induced Cardiac Toxicity in Rats. J Evid Based Integr Med. 2018;23:2156587218757649. doi: 10.1177/2156587218757649.
Albengres E., Tillement J., Le Louet H., Morin D. Trimetazidine: Experimental and Clinical Update Review. Cardiovascular Drug Review. 1998;16(4):359-390.
